These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 31989914)

  • 1. Challenges in the Discovery of Novel Therapeutic Agents in Cancer.
    Nagaraju GP; Kamal MA
    Curr Drug Metab; 2019; 20(12):931-932. PubMed ID: 31989914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The multi-factorial nature of clinical multidrug resistance in cancer.
    Assaraf YG; Brozovic A; Gonçalves AC; Jurkovicova D; Linē A; Machuqueiro M; Saponara S; Sarmento-Ribeiro AB; Xavier CPR; Vasconcelos MH
    Drug Resist Updat; 2019 Sep; 46():100645. PubMed ID: 31585396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
    Bar-Zeev M; Livney YD; Assaraf YG
    Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aptamers as targeting ligands and therapeutic molecules for overcoming drug resistance in cancers.
    Zhou G; Latchoumanin O; Hebbard L; Duan W; Liddle C; George J; Qiao L
    Adv Drug Deliv Rev; 2018 Sep; 134():107-121. PubMed ID: 29627370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor microenvironment and cancer therapy resistance.
    Sun Y
    Cancer Lett; 2016 Sep; 380(1):205-15. PubMed ID: 26272180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach.
    Taylor S; Spugnini EP; Assaraf YG; Azzarito T; Rauch C; Fais S
    Drug Resist Updat; 2015 Nov; 23():69-78. PubMed ID: 26341193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crossroad between linear and nonlinear transcription concepts in the discovery of next-generation sequencing systems-based anticancer therapies.
    Roukos DH
    Drug Discov Today; 2016 Apr; 21(4):663-73. PubMed ID: 26912452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming treatment resistance in cancer: Current understanding and tactics.
    Wu G; Wilson G; George J; Liddle C; Hebbard L; Qiao L
    Cancer Lett; 2017 Feb; 387():69-76. PubMed ID: 27089987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
    Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
    Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug resistance: challenges to effective therapy.
    Shekhar MP
    Curr Cancer Drug Targets; 2011 Jun; 11(5):613-23. PubMed ID: 21486215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategy of Daiichi Sankyo discovery research in oncology.
    Akahane K; Hirokawa K
    Jpn J Clin Oncol; 2014 Feb; 44(2):109-15. PubMed ID: 24459194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges in the Discovery of Novel Therapeutic Agents in Cancer (Part III).
    Kamal MA; Nagaraju GP
    Curr Drug Metab; 2020; 21(1):4-5. PubMed ID: 32423370
    [No Abstract]   [Full Text] [Related]  

  • 14. Establishing patient-tailored variability-based paradigms for anti-cancer therapy: Using the inherent trajectories which underlie cancer for overcoming drug resistance.
    Ilan Y; Spigelman Z
    Cancer Treat Res Commun; 2020; 25():100240. PubMed ID: 33246316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overcoming multidrug resistance in cancer: 35 years after the discovery of ABCB1.
    Gillet JP; Gottesman MM
    Drug Resist Updat; 2012; 15(1-2):2-4. PubMed ID: 22465109
    [No Abstract]   [Full Text] [Related]  

  • 16. New frontiers in therapeutic resistance in cancer.
    Sartore-Bianchi A; Delorenzi M; Gagnon-Kugler T; Rousseau C; Batist G
    Expert Rev Anticancer Ther; 2012 Jul; 12(7):877-9. PubMed ID: 22845402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug discovery strategies in the field of tumor energy metabolism: Limitations by metabolic flexibility and metabolic resistance to chemotherapy.
    Amoedo ND; Obre E; Rossignol R
    Biochim Biophys Acta Bioenerg; 2017 Aug; 1858(8):674-685. PubMed ID: 28213330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoparticle Delivery of TWIST Small Interfering RNA and Anticancer Drugs: A Therapeutic Approach for Combating Cancer.
    Glackin CA
    Enzymes; 2018; 44():83-101. PubMed ID: 30360816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics.
    Wijdeven RH; Pang B; Assaraf YG; Neefjes J
    Drug Resist Updat; 2016 Sep; 28():65-81. PubMed ID: 27620955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming cancer resistance.
    Cook KL; Clarke R
    Future Med Chem; 2015 Aug; 7(12):1471. PubMed ID: 26334204
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.